Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma

Abstract

Combination bevacizumab therapy demonstrated activity in heavily pretreated women with ovarian cancer. Gastrointestinal perforations were identified in 9%. Despite the toxicity of the regimen, prospective studies, particularly in less heavily pretreated patients, are warranted.